Taipei Exchange - Delayed Quote TWD

BIONET Corp. (1784.TWO)

Compare
82.00 +0.50 (+0.61%)
At close: 1:30:24 PM GMT+8
Loading Chart for 1784.TWO
DELL
  • Previous Close 81.50
  • Open 83.00
  • Bid --
  • Ask --
  • Day's Range 81.60 - 83.10
  • 52 Week Range 50.77 - 162.01
  • Volume 176,657
  • Avg. Volume 469,643
  • Market Cap (intraday) 4.055B
  • Beta (5Y Monthly) 0.71
  • PE Ratio (TTM) 78.10
  • EPS (TTM) 1.05
  • Earnings Date --
  • Forward Dividend & Yield 0.71 (0.82%)
  • Ex-Dividend Date Sep 19, 2024
  • 1y Target Est --

BIONET Corp. provides cord blood banking services in Taiwan and internationally. The company offers stem cell banking services, including stem cell storage, mesenchymal stem cell storage, dental stem cell storage, adipose stem cell, and PBSC + immune cells; and genetic testing services. It also provides stem anti-aging and ANIKINE series products. In addition, the company offers Exosome, a novel cell-free therapy. The company was founded in 1989 and is based in Taipei City, Taiwan.

www.bionetcorp.com

--

Full Time Employees

December 31

Fiscal Year Ends

Recent News: 1784.TWO

View More

Performance Overview: 1784.TWO

Trailing total returns as of 1/7/2025, which may include dividends or other distributions. Benchmark is

.

YTD Return

1784.TWO
3.14%
TSEC CAPITALIZATION WEIGHTED ST
1.99%

1-Year Return

1784.TWO
58.38%
TSEC CAPITALIZATION WEIGHTED ST
35.00%

3-Year Return

1784.TWO
139.18%
TSEC CAPITALIZATION WEIGHTED ST
28.76%

5-Year Return

1784.TWO
135.33%
TSEC CAPITALIZATION WEIGHTED ST
97.86%

Compare To: 1784.TWO

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 1784.TWO

View More

Valuation Measures

As of 1/6/2025
  • Market Cap

    4.30B

  • Enterprise Value

    3.05B

  • Trailing P/E

    77.58

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    3.64

  • Price/Book (mrq)

    3.21

  • Enterprise Value/Revenue

    2.59

  • Enterprise Value/EBITDA

    23.85

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    5.40%

  • Return on Assets (ttm)

    1.50%

  • Return on Equity (ttm)

    3.86%

  • Revenue (ttm)

    1.16B

  • Net Income Avi to Common (ttm)

    62.74M

  • Diluted EPS (ttm)

    1.05

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    1.26B

  • Total Debt/Equity (mrq)

    4.87%

  • Levered Free Cash Flow (ttm)

    -69.83M

Research Analysis: 1784.TWO

View More

People Also Watch